However the continued efforts to design potent and specific TGM2 inhibitors could provide exciting opportunities over the coming years to disrupt aberrant BECN1 aggresome formation, restoring normal autophagy, and potentially significantly ameliorating persistent infections and inflammation in CF airways. The gene discussed is TGM2; the disease is cystic fibrosis.